AGF Management Ltd. Invests $2.67 Million in Exact Sciences Co. (NASDAQ:EXAS)

AGF Management Ltd. bought a new position in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 47,466 shares of the medical research company's stock, valued at approximately $2,667,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Geode Capital Management LLC raised its stake in shares of Exact Sciences by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company's stock worth $211,104,000 after acquiring an additional 7,873 shares in the last quarter. Champlain Investment Partners LLC increased its position in shares of Exact Sciences by 10.9% during the third quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company's stock worth $169,924,000 after purchasing an additional 245,980 shares in the last quarter. Bellevue Group AG lifted its holdings in shares of Exact Sciences by 25.1% during the 3rd quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company's stock valued at $98,738,000 after purchasing an additional 290,585 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Exact Sciences by 3.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,330,939 shares of the medical research company's stock worth $74,785,000 after purchasing an additional 38,849 shares in the last quarter. Finally, Groupama Asset Managment acquired a new position in Exact Sciences during the 3rd quarter valued at about $821,000. Institutional investors own 88.82% of the company's stock.

Remove Ads

Exact Sciences Price Performance

Shares of NASDAQ EXAS traded up $0.18 during trading on Monday, hitting $45.18. The company had a trading volume of 1,956,921 shares, compared to its average volume of 2,330,356. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. The stock has a fifty day simple moving average of $51.73 and a two-hundred day simple moving average of $58.82. The firm has a market capitalization of $8.39 billion, a price-to-earnings ratio of -8.11 and a beta of 1.25.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The company had revenue of $713.42 million during the quarter, compared to analyst estimates of $701.45 million. On average, research analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Bank of America lowered their price target on Exact Sciences from $72.00 to $65.00 and set a "buy" rating for the company in a report on Thursday, February 20th. Piper Sandler cut their price target on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Barclays lowered their price objective on shares of Exact Sciences from $70.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Scotiabank raised their target price on Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a research note on Monday, February 24th. Finally, BTIG Research boosted their price target on Exact Sciences from $65.00 to $75.00 and gave the company a "buy" rating in a research note on Tuesday, November 26th. Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $70.83.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.